Ocular Therapeutix (OCUL) announced that its SOL-R registrational trial of AXPAXLI in wet age-related macular degeneration has achieved its randomization target of 555 subjects. Ocular will continue to allow randomization of previously enrolled subjects currently in the loading phase of the trial to maintain its commitment to both patients and investigators, with topline data remaining on track for the first half of 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix reports Q3 EPS (38c), consensus (35c)
- OCUL Earnings this Week: How Will it Perform?
- Ocular Therapeutix price target raised to $20 from $14 at TD Cowen
- Optimistic Buy Rating for Ocular Therapeutix Driven by Axpaxli’s Market Potential in wAMD and NPDR
- Insider Moves: Ross, Carisma, Agree, Aehr, Ocular